JSP191, an investigational therapy by Jasper Therapeutics, showed promising efficacy as a conditioning agent to prepare older patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) for a stem cell transplant. These are the early findings of an ongoing open-label Phase 1 trial, called JSP-CP-003 (NCT04429191), which is currently investigating the safety, tolerability, and efficacy of adding JSP191 to a standard conditioning regimen for older adults with AML or MDS before they undergo a…

You must be logged in to read/download the full post.